SCHEMBL27364042

SCHEMBL27364042

CC(=O)c1cnn(Cc2ccc(C#N)cc2)c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KLKB1 P03952 2/20 0.54
▸ CYP19A1 P11511 5/20 0.48
▸ ITK Q08881 1/20 0.47
▸ SCD O00767 1/20 0.47
▸ CYP11B1 P15538 2/20 0.46
▸ CYP11B2 P19099 2/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.44
▸ MAPT P10636 2/20 0.44
▸ ERCC5 P28715 1/20 0.44
▸ PRKAA2 P54646 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ ACACB O00763 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ ALKBH1 Q13686 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730357 0.87 HSD17B10 (0.57) KLKB1CYP19A1ITKSCDCYP11B1
SCHEMBL19300037 0.84 HSD17B10 (0.51) KLKB1HSD17B10ALDH1A1MAPTLMNA
SCHEMBL30739125 0.84 KLKB1 (0.53) KLKB1CYP19A1ITKSCDCYP11B1
SCHEMBL20529831 0.83 KLKB1 (0.52) KLKB1CYP19A1ITKSCDCYP11B1
SCHEMBL31591075 0.83 KLKB1 (0.52) KLKB1CYP19A1ITKSCDCYP11B1
SCHEMBL27364232 0.82 KLKB1 (0.53) KLKB1HSD17B10ALDH1A1MAPTLMNA
SCHEMBL17229366 0.82 KLKB1 (0.51) KLKB1HSD17B10ALDH1A1MAPTLMNA
SCHEMBL30739156 0.81 KLKB1 (0.51) KLKB1CYP19A1ITKSCDCYP11B1
SCHEMBL30739164 0.81 KLKB1 (0.51) KLKB1CYP19A1ITKSCDCYP11B1
SCHEMBL752774 0.81 LMNA (0.61) KLKB1HSD17B10ALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024026483-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 — — WO disclosed
Send feedback